drugset / Trial / NCT07047989
NWRD09 for HPV-16 Related Cervical HSIL
NaSequentialOpen-labelTreatment
Summary
This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial lesions (HSlL).
Timeline
- Start
- 2025-06-12
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NWRD09 | Messenger RNA (mRNA) | — | Intramuscular |